Market Cap
€45.9m
Last Updated
2020/11/26 19:09 UTC
Data Sources
Company Financials +
Executive Summary
Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. More Details
Risk Analysis
Earnings are forecast to decline by an average of 59.6% per year for the next 3 years
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Valbiotis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALVAL is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ALVAL's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
3.4%
ALVAL
0.4%
FR Biotechs
0.4%
FR Market
1 Year Return
172.1%
ALVAL
27.7%
FR Biotechs
-3.0%
FR Market
Return vs Industry: ALVAL exceeded the French Biotechs industry which returned 27.7% over the past year.
Return vs Market: ALVAL exceeded the French Market which returned -3% over the past year.
Shareholder returns
| ALVAL | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.4% | 0.4% | 0.4% |
| 30 Day | 2.7% | 7.8% | 13.2% |
| 90 Day | 37.0% | 18.5% | 11.0% |
| 1 Year | 172.1%172.1% | 27.8%27.7% | -1.0%-3.0% |
| 3 Year | -12.7%-13.5% | -35.9%-36.0% | 16.6%6.9% |
| 5 Year | n/a | -66.0%-66.2% | 44.5%24.8% |
Long-Term Price Volatility Vs. Market
How volatile is Valbiotis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Valbiotis SA's (EPA:ALVAL) Profit Outlook5 months ago | Simply Wall St
Is Valbiotis (EPA:ALVAL) Using Too Much Debt?7 months ago | Simply Wall St
Do Directors Own Valbiotis SA (EPA:ALVAL) Shares?Valuation
Is Valbiotis undervalued compared to its fair value and its price relative to the market?
7.81x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALVAL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALVAL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALVAL is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: ALVAL is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALVAL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALVAL is overvalued based on its PB Ratio (7.8x) compared to the FR Biotechs industry average (3x).
Next Steps
Future Growth
How is Valbiotis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-59.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALVAL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALVAL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALVAL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALVAL's revenue is expected to decline over the next 3 years (-12.5% per year).
High Growth Revenue: ALVAL's revenue is forecast to decline over the next 3 years (-12.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALVAL's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Valbiotis performed over the past 5 years?
-44.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALVAL is currently unprofitable.
Growing Profit Margin: ALVAL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALVAL is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare ALVAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALVAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).
Return on Equity
High ROE: ALVAL has a negative Return on Equity (-102.4%), as it is currently unprofitable.
Next Steps
Financial Health
How is Valbiotis's financial position?
Financial Position Analysis
Short Term Liabilities: ALVAL's short term assets (€12.6M) exceed its short term liabilities (€7.4M).
Long Term Liabilities: ALVAL's short term assets (€12.6M) exceed its long term liabilities (€3.6M).
Debt to Equity History and Analysis
Debt Level: ALVAL's debt to equity ratio (36.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ALVAL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ALVAL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ALVAL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.2% per year.
Next Steps
Dividend
What is Valbiotis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALVAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALVAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALVAL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALVAL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALVAL's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Sébastien Peltier (42 yo)
no data
Tenure
Mr. Sébastien Peltier, Ph.D., HDR serves as the Chief Executive Officer and Chairman of Valbiotis SA. Mr. Peltier joined Laboratoire Lescuyer in 2007 and served as its in charge of the Research & Developme...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | no data | no data | 9.21% € 4.2m | |
| CFO & Director | no data | no data | 4.6% € 2.1m | |
| CSO & Director | 2.17yrs | no data | no data | |
| CMO & Director | 1.75yrs | no data | no data | |
| Head of Global Business Development | 1.83yrs | no data | no data | |
| Executive Director of Credit Mutuel & Equity SCR and Member of Supervisory Board | 1.67yrs | no data | no data | |
| Chief Executive Officer of Alliance Consulting | no data | no data | no data |
1.8yrs
Average Tenure
Experienced Management: ALVAL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | no data | no data | 9.21% € 4.2m | |
| CFO & Director | no data | no data | 4.6% € 2.1m | |
| CSO & Director | 2.17yrs | no data | no data | |
| CMO & Director | 1.75yrs | no data | no data | |
| Executive Director of Credit Mutuel & Equity SCR and Member of Supervisory Board | 1.67yrs | no data | no data | |
| Chairman of Supervisory Board | 3.67yrs | no data | no data | |
| Member of Scientific & Medical Board | no data | no data | no data | |
| Member of Scientific & Medical Board | no data | no data | no data | |
| Member of Scientific & Medical Board | no data | no data | no data | |
| Member of Scientific & Medical Board | no data | no data | no data | |
| Member of Scientific & Medical Board | no data | no data | no data | |
| Member of Scientific & Medical Board | no data | no data | no data |
2.0yrs
Average Tenure
47yo
Average Age
Experienced Board: ALVAL's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 85.9%.
Top Shareholders
Company Information
Valbiotis SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Valbiotis SA
- Ticker: ALVAL
- Exchange: ENXTPA
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €45.935m
- Shares outstanding: 7.66m
- Website: https://valbiotis.com
Number of Employees
Location
- Valbiotis SA
- rue Paul Vatine
- 12th Floor
- Périgny
- Auvergne
- 17180
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ALVAL | ENXTPA (Euronext Paris) | Yes | Common Shares | FR | EUR | Jun 2017 |
Biography
Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/26 19:09 |
| End of Day Share Price | 2020/11/26 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.